Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorNanfang Hospital, Southern Medical University
About this trial
Plasma contains a variety of metabolites, among which sphingolipids, including ceramide, sphingosine, and sphingosine-1-phosphate, serve as important intracellular second messengers and are involved in various cellular signaling pathways, such as apoptosis. We hypothesize that plasma sphingolipid levels may be associated with the efficacy of radiotherapy for liver cancer. This study will utilize LC-MS/MS technology for qualitative and quantitative analysis of plasma sphingolipids in liver cancer patients undergoing radiotherapy. Clinical data related to patient prognosis will also be collected to investigate the correlation between plasma sphingolipid levels and the therapeutic efficacy of liver cancer radiotherapy. The aim is to establish the clinical diagnostic significance of plasma sphingolipid levels in predicting the efficacy of liver cancer radiotherapy, providing new insights to enhance the effectiveness of radiotherapy in liver cancer treatment.
Eligibility criteria
Qualifiers
Patients voluntarily signed the informed consent form.
Aged between 18 and 80 years.
Clinically diagnosed with primary liver cancer according to the latest treatment guidelines.
Determined by the treating physician to require radiotherapy.
Disqualifiers
Patients who discontinued radiotherapy or did not complete the planned treatment.
Presence of malignancies from other origins.
Severe metabolic diseases such as uncontrolled diabetes, significant obesity, or fatty liver disease.
Uncontrolled comorbidities, such as severe cardiovascular or pulmonary diseases, that may affect treatment or study outcomes.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
260 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov